Extending dosing intervals reduces deadly side effect risk from multiple sclerosis drug
(NYU Langone Health / NYU School of Medicine) A commonly-prescribed multiple sclerosis (MS) infusion medication, natalizumab, linked to a rare but serious side effect is safer to use when dosing intervals are extended, according to a new study led by MS specialists at NYU Langone Health. (Source: EurekAlert! - Medicine and Health)
Source: EurekAlert! - Medicine and Health - February 2, 2018 Category: International Medicine & Public Health Source Type: news
Rituximab Outperforms Other Drugs in RRMS Rituximab Outperforms Other Drugs in RRMS
In a new study, rituximab was superior to other drugs -- including fingolimod, natalizumab, and dimethyl fumarate -- in efficacy, safety, and tolerability in patients with relapsing-remitting MS.Medscape Medical News (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - January 11, 2018 Category: Consumer Health News Tags: Neurology & Neurosurgery News Source Type: news
Dimethyl Fumarate: A Possible Exit Strategy From Natalizumab Dimethyl Fumarate: A Possible Exit Strategy From Natalizumab
Is dimethyl fumarate effective in preventing disease rebound after natalizumab discontinuation in patients with MS?Journal of Neurology, Neurosurgery, and Psychiatry (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - December 22, 2017 Category: Consumer Health News Tags: Neurology & Neurosurgery Journal Article Source Type: news
FDA Drug Safety Communication: New risk factor for Progressive Multifocal Leukoencephalopathy (PML) associated with Tysabri (natalizumab)
[01-20-2012] The U.S. Food and Drug Administration (FDA) is informing the public that testing positive for anti-JC virus (JCV) antibodies has been identified as a risk factor for progressive multifocal leukoencephalopathy (PML). (Source: FDA Center for Drug Evaluation and Research - What's New)
Source: FDA Center for Drug Evaluation and Research - What's New - December 11, 2017 Category: Drugs & Pharmacology Source Type: news
Natalizumab Beneficial in Secondary Progressive MS? Natalizumab Beneficial in Secondary Progressive MS?
A new post hoc analysis of the ASCEND trial in secondary progressive multiple sclerosis suggests that natalizumab is effective in this population, particularly for upper limb function.Medscape Medical News (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - November 21, 2017 Category: Consumer Health News Tags: Neurology & Neurosurgery News Source Type: news
PML Reported in Patient Receiving Ocrelizumab PML Reported in Patient Receiving Ocrelizumab
But the case could be attributable to ' carryover ' from the patient ' s previous treatment with natalizumab, the company said.Medscape Medical News (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - May 25, 2017 Category: Consumer Health News Tags: Neurology & Neurosurgery News Source Type: news
Genentech Reports PML Case with Ocrelizumab
(MedPage Today) -- Occurred in patient transitioning from natalizumab (Source: MedPage Today Primary Care)
Source: MedPage Today Primary Care - May 24, 2017 Category: Primary Care Source Type: news
Enhanced Atypical Lymphocytes in Natalizumab - Treated MS
Enhanced fraction of atypical lymphocytes, especially binucleated and plasmacytoid lymphocytes (Source: The Doctors Lounge - Oncology)
Source: The Doctors Lounge - Oncology - May 24, 2017 Category: Cancer & Oncology Tags: Internal Medicine, Neurology, Oncology, Pathology, Pharmacy, Journal, Source Type: news
March's top stories: Perrigo's $2.85bn sale, Cancer Research UK's Precision Panc project
Perrigo completed the sale of Tysabri drug royalty to RPI for $2.85bn, London's Institute of Cancer Research (ICR) revealed new secrets about the genetic causes of cancer, and Eli Lilly acquired CoLucid Pharmaceuticals for $960m. Pharmaceutical-techn … (Source: Pharmaceutical Technology)
Source: Pharmaceutical Technology - April 2, 2017 Category: Pharmaceuticals Source Type: news
Perrigo completes sale of Tysabri drug royalty to RPI for $2.85bn
Drug manufacturer Perrigo has completed the sale of its right to the royalty stream from the global net sales of the drug Tysabri (natalizumab) to Royalty Pharma's (RPI) affiliate RPI Finance Trust for $2.85bn. (Source: Pharmaceutical Technology)
Source: Pharmaceutical Technology - March 27, 2017 Category: Pharmaceuticals Source Type: news
Perrigo to sell Tysabri drug royalty to RPI for $2.85bn
Ireland-based Perrigo has signed an agreement to sell its right to the royalty stream from the global net sales of the multiple sclerosis drug Tysabri (natalizumab) to Royalty Pharma ’s (RPI) affiliate RPI Finance Trust for $2.85bn. (Source: Pharmaceutical Technology)
Source: Pharmaceutical Technology - March 1, 2017 Category: Pharmaceuticals Source Type: news
Federal investigators subpoena Biogen over MS drug prices
Biogen (NSDQ:BIIB) said on Thursday that it received a subpoena in December last year from federal investigators about the prices of its top-selling multiple sclerosis drugs, Tecfidera, Avonex, Tysabri and Plegridy.
In its annual regulatory filing, the company wrote that the investigators inquired about “government price reporting, rebate payments and Biogen’s co-pay assistance programs.” While Cambridge, Mass.-based Biogen said it was cooperating with the federal probe, it did not provide any other specific details.
Get the full story at our sister site, Drug Delivery Business News.
The post Federal ...
Source: Mass Device - February 3, 2017 Category: Medical Equipment Authors: Sarah Faulkner Tags: Legal News Neurological Pharmaceuticals Wall Street Beat Biogen Source Type: news
Biogen subpoenaed by federal government over MS drug prices
Biogen disclosed Thursday that it received a subpoena late last year from federal investigators related to the price of its top multiple sclerosis drugs, including blockbuster treatment Tecfidera.
Cambridge-based Biogen (Nasdaq: BIIB) said in its annual federal filing that it had received a subpoena on Dec. 5 seeking information regarding "government price reporting, rebate payments and Biogen's co-pay assistance programs" for MS drugs Tecfidera, Avonex, Tysabri and Plegridy. The company sa id it… (Source: bizjournals.com Health Care:Biotechnology headlines)
Source: bizjournals.com Health Care:Biotechnology headlines - February 2, 2017 Category: Biotechnology Authors: Max Stendahl Source Type: news
Biogen subpoenaed by federal government over MS drug prices
Biogen disclosed Thursday that it received a subpoena late last year from federal investigators related to the price of its top multiple sclerosis drugs, including blockbuster treatment Tecfidera.
Cambridge-based Biogen (Nasdaq: BIIB) said in its annual federal filing that it had received a subpoena on Dec. 5 seeking information regarding "government price reporting, rebate payments and Biogen's co-pay assistance programs" for MS drugs Tecfidera, Avonex, Tysabri and Plegridy. The company sa id it… (Source: bizjournals.com Health Care:Physician Practices headlines)
Source: bizjournals.com Health Care:Physician Practices headlines - February 2, 2017 Category: American Health Authors: Max Stendahl Source Type: news
Elevated Natalizumab Levels in MS May Not Be Linked With PML Risk Elevated Natalizumab Levels in MS May Not Be Linked With PML Risk
In multiple sclerosis (MS) patients treated with natalizumab, the risk of developing progressive multifocal leukoencephalopathy (PML) does not appear to be associated with high blood levels of the drug, preliminary research from the Netherlands suggests.Reuters Health Information (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - January 3, 2017 Category: Consumer Health News Tags: Neurology & Neurosurgery News Source Type: news
